TheracosBio announced that Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 inhibitor, is now available by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).
A 30-day supply is available from Cost Plus Drugs for $47.85 plus shipping and handling.
“The commercialization of Brenzavvy marks the first phase of the TheracosBio program to bring cost-effective novel medications to the U.S. population, expanding markets by reducing barriers to greater utilization,” said Albert Collinson, president and CEO of TheracosBio. “We develop new drugs in an efficient manner that produces savings for patients, and we’re pleased to begin working with Cost Plus Drugs to make Brenzavvy accessible.”
[Read more: Diabetes goes digital: Innovative technologies are revolutionizing diabetes care and monitoring]
Brenzavvy is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. Brenzavvy is not recommended for patients with Type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.
Brenzavvy is available as 20 mg oral tablets recommended to be taken once daily, in the morning with or without food.
"We are excited to offer Brenzavvy to our patients with diabetes," said Mark Cuban, co-founder of Mark Cuban Cost Plus Drug Company. "TheracosBio is breaking new ground by making this product available to consumers at a transparent, low price. We look forward to working with them as we continue to add more branded drugs to costplusdrugs.com."
[Read more: Diabetes care goes beyond medical devices]
“Our main goal is to make as many products as possible available to those who need them at an affordable price. I’m a diabetic myself, so products like Brenzavvy are a top priority, ” said Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drug Company. “We appreciate TheracosBio’s commitment to accessibility as demonstrated by making this new medication available to Cost Plus Drugs users, no insurance required.”